NASDAQ:FATE Fate Therapeutics Q3 2024 Earnings Report $1.17 -0.08 (-6.40%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.06 (+4.70%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Fate Therapeutics EPS ResultsActual EPS-$0.40Consensus EPS -$0.42Beat/MissBeat by +$0.02One Year Ago EPSN/AFate Therapeutics Revenue ResultsActual Revenue$3.07 millionExpected Revenue$0.88 millionBeat/MissBeat by +$2.19 millionYoY Revenue GrowthN/AFate Therapeutics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time3:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Fate Therapeutics Earnings HeadlinesFate Therapeutics (NASDAQ:FATE) Upgraded at StockNews.comMay 18 at 3:33 AM | americanbankingnews.comQ2 Earnings Estimate for Fate Therapeutics Issued By WedbushMay 18 at 1:57 AM | americanbankingnews.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.May 21, 2025 | Weiss Ratings (Ad)Robert W. Baird Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $4.00May 17, 2025 | americanbankingnews.comFate Therapeutics' (FATE) "Hold" Rating Reiterated at Needham & Company LLCMay 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for FATE Q2 Earnings?May 17, 2025 | americanbankingnews.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings Autodesk (5/22/2025)Analog Devices (5/22/2025)Copart (5/22/2025)Intuit (5/22/2025)Ross Stores (5/22/2025)Workday (5/22/2025)Toronto-Dominion Bank (5/22/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
